160 completed. 160 Phase 2, 10 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 160 | Completed 160 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 1 | Completed 1 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumor(GIST) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 108 | 2020-11-25 | 2026-04-03 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion GB-102 - Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Completed | Graybug Vision | 21 | 2019-09-11 | 2021-11-22 |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing Sunitinib - Carcinoma, Renal Cell | Phase 2 | Completed | Duke University | 7 | 2017-09-27 | 2024-10-08 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer Nivolumab, Ipilimumab, Pazopanib - Clear Cell Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 200 | 2017-05-31 | 2021-04-26 |
| Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Sunitinib - Clear Cell Renal Carcinoma | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 23 | 2017-05-10 | 2020-11-13 |
| Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer Sunitinib, Gefitinib, Imatinib - Stomach Neoplasms | Phase 2 | Completed | Samsung Medical Center | 66 | 2017-03-01 | 2022-06-15 |
| Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib Sunitinib - Pancreatic Neuroendocrine Tumour Metastatic | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 11 | 2017-02-14 | 2020-03-04 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| Testosterone in Metastatic Renal Cell Carcinoma Patients Testosterone undecanoate and sunitinib or pazopanib - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Kidney Cancer Research Bureau | 60 | 2016-02-08 | 2019-10-22 |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Sunitinib - Thymic Carcinoma | Phase 2 | Completed | Seoul National University Hospital | 25 | 2015-10-01 | 2019-01-23 |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours TH-302 + Sunitinib - Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 17 | 2015-05-11 | 2020-07-27 |
| Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) Intuvax (INN: ilixadencel), Sunitinib - Renal Cell Carcinoma, Metastatic | Phase 2 | Completed | Mendus | 88 | 2015-04-01 | 2022-08-22 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors CGT9486, Pexidartinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | Cogent Biosciences, Inc. | 51 | 2015-03-06 | 2025-02-14 |
| Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate - Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 84 | 2015-02-01 | 2025-04-20 |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) Sunitinib, Questionnaire - Genitourinary Cancer, Kidney Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 60 | 2014-08-01 | 2020-02-27 |
| CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) CRLX101, Bevacizumab, Standard of Care (Investigator Choice) - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | NewLink Genetics Corporation | 115 | 2014-07-01 | 2020-05-28 |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy EMA-approved ATI based targeted therapy - Metastatic Cancer | Phase 2 | Completed | Oslo University Hospital | 50 | 2014-05-01 | 2019-03-13 |
| A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, Sunitinib - Renal Cell Carcinoma | Phase 2 | Completed | Hoffmann-La Roche | 305 | 2014-01-08 | 2019-12-23 |
Showing 20 of 160. Sign in to see all of them.
Carcinoma, Renal Cell (39) · Kidney Neoplasms (13) · Neoplasm Metastasis (13) · Breast Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (7) · Urinary Bladder Neoplasms (7) · Gastrointestinal Stromal Tumors (6) · Prostatic Neoplasms (6) · Ovarian Neoplasms (5) · Small Cell Lung Carcinoma (5) · Brain Neoplasms (4) · Esophageal Neoplasms (4) · Liver Neoplasms (4) · Lung Neoplasms (4)
Pfizer (25) · National Cancer Institute (NCI) (23) · Memorial Sloan Kettering Cancer Center (7) · Central European Society for Anticancer Drug Research (4) · Case Comprehensive Cancer Center (3) · Dana-Farber Cancer Institute (3) · Duke University (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · Massachusetts General Hospital (3) · Samsung Medical Center (3) · US Oncology Research (3) · University Health Network, Toronto (3) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (2) · Graybug Vision (2)
United States (88) · France (25) · Canada (22) · Germany (15) · Spain (14) · Italy (13) · South Korea (12) · United Kingdom (10) · Japan (6) · Netherlands (6) · Taiwan (6) · Poland (5) · China (4) · Czechia (4) · Hungary (4)
Robert J. Motzer, MD (3) · Arun Rajan, M.D. (2) · Dean F. Bajorin, MD (2) · Enrique Grande, MD (2) · Guru Sonpavde, MD (2) · Markus Moehler, MD (2) · Alain Ravaud, MD, PhD (1) · Alain Ravaud, Pr. (1) · Alba Rubio (1) · Alberto Chiappori, M.D. (1) · Alice P Chen, M.D. (1)
PMID 37146227, PMID 25577718, PMID 27238653, PMID 28410911, PMID 33852135, PMID 16757724, PMID 19403935, PMID 19451429, PMID 19536893, PMID 19547919, PMID 19586800, PMID 19652072, PMID 20142724, PMID 20189981, PMID 20203173, PMID 20652398, PMID 20711632, PMID 20975250, PMID 21148613, PMID 21174224, PMID 21512407, PMID 21531821, PMID 21664867, PMID 21787417, PMID 21898376, PMID 22176869, PMID 22261812, PMID 22377563, PMID 22425095, PMID 22537162, PMID 22614181, PMID 22761653, PMID 22837187, PMID 22897944, PMID 22984218, PMID 23182663, PMID 23228299, PMID 23228446, PMID 23269537, PMID 23625328, PMID 23660867, PMID 23788751, PMID 23842041, PMID 23958375, PMID 24268852, PMID 24606768, PMID 24821582, PMID 24882554, PMID 25049330, PMID 25122671
P30CA008748 (4), U10CA031946 (4), N01CM62201 (3), N01CM62203 (3), U10CA180821 (3), 2008 (2), 2009 (2), 2014 (2), P30CA014599 (2), P30CA043703 (2), U10CA027469 (2), 2015 (1), 2016 (1), N01CM00038 (1), N01CM62202 (1)